Categories
Health

Novartis CEO says Covid-related physician go to delays seemingly impacting most cancers analysis charges

The health-care system is still seeing lower rates of diagnoses for certain conditions after the coronavirus pandemic kept non-Covid patients away from the hospital early on, Novartis CEO Vasant Narasimhan told CNBC on Wednesday.

“I think the signals that were sent that ultimately asked patients to stay away from the emergency room, stay away from hospitals, sent a very powerful message to patients not to get the care that they needed,” Narasimhan said on “Closing Bell.” “It may have been appropriate given the public health emergency, but over time what that does is it creates a significant need for better treatments for these patients.”

Narasimhan, who joined Novartis in 2005, said that while trends are positive, lower rates of diagnoses in areas such as cardiovascular disease and oncology remain. For the latter, he said diagnoses are still 30% to 40% lower than pre-Covid-19 levels. Novartis makes cancer treatments.

Nearly 1 in 3 Americans between the ages of 50 and 80 delayed an in-person medical visit last year due to worries about exposure to Covid, according to a poll from the National Poll on Healthy Aging based at the University of Michigan Institute for Healthcare Policy and Innovation. The poll, taken in January, found that 24% of people with cancer and 30% of people with heart conditions had delayed at least one in-person visit.

“Cancer patients that are diagnosed later tend to have worse outcomes, similarly for cardiovascular disease patients that don’t get the therapies that they need,” Narasimhan said. “That in turn creates more burden on the health-care systems over time.”

As Covid cases increase in the U.S. and around the world due to the highly transmissible delta variant, Narasimhan hopes lessons from the early stages of the health crisis have been learned. “I think it’s critical now, this time around, we ensure patients can maintain their care even as the pandemic ebbs and flows over the coming months,” he said.

“We remain optimistic that even as we go through various waves of Covid that the health-care systems have learned that we need to maintain care for noncommunicable diseases, other chronic diseases,” he added.” “Otherwise in effect we create another epidemic, a syndemic so to speak, of these other diseases.”

On Wednesday, Novartis beat analyst expectations for second-quarter revenue and earnings. Narasimhan said the Swiss drugmaker witnessed a resurgence in demand across many therapeutic areas, and noted the company had 9% growth in sales and 13% growth in operating income. 

Novartis is currently involved in manufacturing the Pfizer-BioNTech Covid vaccines, and is assisting CureVac in making vaccines, as well. Novartis also produces monoclonal antibodies to treat Covid for partner companies,” Narasimhan said. “We’re doing a lot, but also ready to do more if needed.”

Categories
Health

DOJ expenses 14 individuals in alleged Covid-related health-care fraud

Paul Hennessy | LightRocket | Getty Images

Federal prosecutors have charged 14 people — including a medical doctor and owners of laboratories, pharmacies and a home health agency — in multiple Covid-related fraud schemes that allegedly bilked consumers and insurers out of $143 million, the Department of Justice announced Wednesday.

In addition, the Center for Program Integrity at the Centers for Medicare & Medicaid Services announced it took administrative action against more than 50 medical providers for their involvement in health-care fraud schemes relating to Covid-19.

The DOJ’s Fraud Section, which leads the Medicare Fraud Strike Force, announced it is prosecuting cases in the following districts: Western District of Arkansas, Northern District of California, Middle District of Louisiana, Central District of California, Southern District of Florida, District of New Jersey and the Eastern District of New York.

“These medical professionals, corporate executives, and others allegedly took advantage of the COVID-19 pandemic to line their own pockets instead of providing needed health care services during this unprecedented time in our country,” Deputy Attorney General Lisa Monaco said. “We are determined to hold those who exploit such programs accountable to the fullest extent of the law.”

FBI Director Christopher Wray also said the agency is committed to combating Covid-related health-care fraud. “Medical providers have been the unsung heroes. … It’s disheartening that some have abused their authorities.”

The defendants allegedly engaged in various types of schemes “designed to exploit the COVID-19 pandemic,” the DOJ said in a news release.

“For example, multiple defendants offered COVID-19 tests to Medicare beneficiaries at senior living facilities, drive-through COVID-19 testing sites, and medical offices to induce the beneficiaries to provide their personal identifying information and a saliva or blood sample,” the DOJ said. “The defendants are alleged to have then misused the information and samples to submit claims to Medicare for unrelated, medically unnecessary, and far more expensive laboratory tests, including cancer genetic testing, allergy testing, and respiratory pathogen panel tests.” The DOJ said the proceeds of the schemes were allegedly laundered through shell corporations and used to buy exotic cars and luxury real estate.

In another example, a defendant allegedly exploited telehealth regulation expansions to submit fraudulent claims to Medicare for telemedicine encounters that never happened, according to the DOJ. Telehealth regulations had been broadened after Covid-19 was recognized as a national emergency to give Medicare beneficiaries greater access to a wider range of services so they could avoid risky travel to health-care sites.

Here are some of the cases the DOJ announced it is prosecuting:

In Arkansas, a man who owns two testing laboratories was charged with health-care fraud in connection with an alleged scheme to defraud the U.S. of more than $88 million. The man allegedly used access to beneficiary and medical provider information from prior lab testing orders to submit hundreds of fraudulent claims for urine, drug and other tests. Some of the falsely submitted claims were for beneficiaries who were already dead.

A doctor in New Jersey allegedly ordered expensive and medically unnecessary cancer genetic testing for Medicare beneficiaries that attended a Covid-19 testing event that he participated in. The man also allegedly billed Medicare for services to beneficiaries that he never provided, totaling about $19 million in health-care fraud schemes.

Another man in the state who was a partner at a diagnostic testing lab allegedly offered kickbacks in exchange for respiratory pathogen tests that were improperly bundled with Covid tests and billed to Medicare. The man allegedly paid and received bribes in a scheme totaling $5.4 million.

In New York, charges were brought against two people who owned several pharmacies and sham pharmacy wholesaling companies for allegedly committing health-care fraud, wire fraud and money laundering totaling $45 million. The two and their co-conspirators allegedly acquired billing privileges for multiple pharmacies. They also allegedly submitted fraudulent claims to Medicare by abusing emergency Covid-19 rules to avoid otherwise applicable limits on refills for expensive drugs. The DOJ news release said the defendants “allegedly used an elaborate network of international money laundering operations to conceal and disguise the proceeds of the scheme.”

Categories
Business

Rising economic system will make up for Covid-related workplace cuts: Cushman & Wakefield CEO

Brett White, CEO of Cushman & Wakefield, on Friday gave a positive long-term outlook for the commercial real estate market, telling CNBC he expected a booming economy to compensate for companies reducing their office needs due to remote working.

“If we think about the close proximity … we see a 10 to 15% reduction in the demand for office space,” White said in an interview with Closing Bell.

“But it’s important to remember that over the next two to three years this will be completely mitigated by the job creation that the US economy and the world economy will create,” added White, who directs the global commercial Real estate company since 2015.

White’s comments on Friday came in response to a question about recent remarks by Jamie Dimon, chairman and chief executive officer of JPMorgan Chase. In his annual letter to the bank’s shareholders, Dimon said JPMorgan would introduce more open seating arrangements in its offices, among other adjustments related to the Covid pandemic.

“As a result, we may only need 60 seats for an average of 100 employees. This will significantly reduce our real estate needs,” wrote Dimon in the letter, which also discussed what he sees as the benefits of being based in the EU office and shortcomings in remote working.

Dimon’s insight into how the country’s largest bank by assets is thinking about Covid-related changes to its business comes as more people are vaccinated against the coronavirus. This is seen as a crucial step in getting employees back into the office, at least part-time, after the pandemic led to widespread adoption of remote working in white-collar jobs last year.

The pandemic will continue to affect the commercial real estate market in 2021 and through 2022, White said. He noted, however, that while some companies are reducing their office needs by adopting more flexible work policies, there are companies like Facebook that have signed leases for additional space.

“The commercial real estate market is driven by a variety of dynamics,” said White, an industry veteran who was CBRE CEO from 2005 to 2012. .. but then we also have this economy, which is now absolutely roaring back and creating new jobs. “

“So, yes, you will see buildings that have more vacant space this year and probably next year than they have in a long time,” he added. “But in the meantime, two to three years, this space should be taken again.”

Cushman & Wakefield’s shares rose 1.26% on Friday, trading at nearly $ 17 apiece. The stock is up 14.23% since the beginning of the year. The Chicago-based company is expected to post a profit for the first quarter on May 6th.